Verition Fund Management
TBPH icon

Verition Fund Management’s Theravance Biopharma TBPH Stock Holding History

Verition Fund Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-110,000
Closed -$1.79M – 2494
2026
Q1 		$1.79M Buy
+110,000
New +$1.95M 0.01% 1082
2025
Q2 		– Sell
-14,647
Closed -$131K – 3861
2025
Q1 		$131K Buy
+14,647
New +$136K ﹤0.01% 3134
2024
Q4 		– Sell
-12,642
Closed -$102K – 3518
2024
Q3 		$102K Sell
12,642
-21,694
-63% -$188K ﹤0.01% 2992
2024
Q2 		$291K Buy
+34,336
New +$310K ﹤0.01% 2366
2023
Q1 		– Sell
-11,261
Closed -$126K – 2541
2022
Q4 		$126K Buy
+11,261
New +$118K ﹤0.01% 1822

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Verition Fund Management's TBPH Position: Q2 2026 in Review

Verition Fund Management sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 110,000 shares — an estimated $1.79M sold.

Verition Fund Management first reported a position in TBPH in Q4 2022 and held it in 5 quarters. The position peaked at $1.79M in Q1 2026. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Verition Fund Management reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Verition Fund Management sold 110,000 Theravance Biopharma shares in Q2 2026, an estimated $1.79M.
  • Verition Fund Management first reported a position in Theravance Biopharma in Q4 2022 and held it in 5 quarters.
  • Verition Fund Management's Theravance Biopharma position peaked at $1.79M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.